Retatrutide (60mg)

Retatrutide is a synthetic peptide that acts as a triple agonist at the GLP-1, GIP, and glucagon receptors simultaneously. This tri-receptor activity profile is what separates it from earlier compounds like semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP), and is the basis for the significant fat loss results observed in Phase 2 clinical trials.

Simple: it's the best value format we offer, and it's enough for a full extended protocol without running out. At $559.99 for 60mg — roughly $9.33 per milligram — you're getting six times the compound compared to a single 10mg vial, for about four times the price. If you're planning a 12-week or longer research window, the 60mg vial means one order, one batch, consistent purity from start to finish. No reordering mid-protocol, no waiting on restocks.

Phase 2 clinical trials observed mean body weight reductions of up to 24% over 48 weeks — significantly outperforming semaglutide and tirzepatide in head-to-head comparisons. Subjects also showed dramatic reductions in waist circumference, visceral fat, and improvements across key cardiometabolic markers. The appetite suppression observed was described as profound, with energy intake reductions sustained throughout the trial period. No other compound in its class has matched these results in clinical trial data.

Retatrutide hits three separate pathways at once — GLP-1 receptors to suppress appetite and slow digestion; GIP receptors to improve insulin sensitivity and amplify fat loss; and glucagon receptors to increase energy expenditure by driving the liver to burn more fuel. Most weight loss compounds only target one or two of these. Retatrutide targets all three simultaneously, which is why the Phase 2 results were so far ahead of anything that came before it.

Semaglutide (Ozempic/Wegovy) is a GLP-1 only agonist — one receptor. Tirzepatide (Mounjaro) targets GLP-1 and GIP — two receptors. Retatrutide targets GLP-1, GIP, and glucagon — three receptors. In Phase 2 trials, Retatrutide produced a mean 24% body weight reduction over 48 weeks; tirzepatide achieved around 20% in comparable studies, and semaglutide around 14–15%. The addition of glucagon receptor activity — which drives energy expenditure directly — is the key difference.

Retatrutide is supplied as a lyophilized powder and should be reconstituted with bacteriostatic water (BAC water) immediately before use. Inject the BAC water slowly into the vial, directing the stream down the inside wall. Gently swirl to dissolve — do not shake. Once reconstituted, store at 2–8°C and use within 28 days. For a full step-by-step walkthrough, see our complete peptide reconstitution guide.

Store lyophilized Retatrutide vials at -20°C, away from light and moisture. After reconstitution, refrigerate at 2–8°C and use within 28 days. Do not freeze reconstituted solution.

Retatrutide (60mg) is available through Aussie Peptides with fast domestic shipping to all Australian states and territories. Every vial is dispatched from within Australia — no customs delays, no international freight uncertainty. Each batch undergoes third-party analysis and the Certificate of Analysis is available to view in our CoA library.

Retatrutide (60mg) is priced at $549.99 per vial, which works out to approximately $9.17 per milligram at Aussie Peptides.